Akèy › Sendwòm myelodisplastik
Etid klinik pou Sendwòm myelodisplastik ap rekrite nan Etazini
157 etid pou Sendwòm myelodisplastik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX43 etid
- Baldwin Park, CA26 etid
- New York City, NY21 etid
- Seattle, WA21 etid
- Washington, DC20 etid
- Boston, MA19 etid
- Tampa, FL19 etid
- Miami, FL17 etid
- Columbus, OH14 etid
- Durham, NC14 etid
- Chicago, IL13 etid
- Atlanta, GA13 etid
- St. Louis, MO13 etid
- Cleveland, OH11 etid
- Nashville, TN11 etid
- Philadelphia, PA10 etid
- Birmingham, AL10 etid
- Los Angeles, CA10 etid
- Mountain View, CA9 etid
- Pittsburgh, PA9 etid
- Baltimore, MD9 etid
- Winston-Salem, NC9 etid
- Jacksonville, FL9 etid
- The Bronx, NY9 etid
- Portland, OR8 etid
- Buffalo, NY8 etid
- New Haven, CT8 etid
- Milwaukee, WI8 etid
- Minneapolis, MN8 etid
- Salt Lake City, UT8 etid
- Memphis, TN7 etid
- Clifton, NJ7 etid
- Cedar Rapids, IA7 etid
- Edison, NJ7 etid
- Orange, CA7 etid
- Kansas City, MO7 etid
- San Francisco, CA6 etid
- Aurora, CO6 etid
- Rochester, NY6 etid
- Queens, NY6 etid
Pa eta
- Alabama10 etid
- Arizona9 etid
- Arkansas4 etid
- Ayiti3 etid
- Colorado8 etid
- Connecticut10 etid
- Distrik Columbia4 etid
- Florid31 etid
- Georgia15 etid
- Idaho4 etid
- Illinois16 etid
- Indiana4 etid
- Iowa7 etid
- Kalifòni41 etid
- Kansas5 etid
- Kentucky5 etid
- Lwizyàn5 etid
- Main4 etid
- Maryland23 etid
- Massachusetts21 etid
- Michigan8 etid
- Minnesota13 etid
- Mississippi3 etid
- Missouri15 etid
- Montana3 etid
- Nebraska4 etid
- Nevada3 etid
- New Hampshire5 etid
- New Jersey13 etid
- New Mexico4 etid
- New York38 etid
- North Carolina19 etid
- North Dakota4 etid
- Ohio22 etid
- Oklahoma4 etid
- Oregon10 etid
- Pennsylvania17 etid
- Rhode Island4 etid
- South Carolina7 etid
- Tennessee15 etid
- Texas44 etid
- Utah8 etid
- Vermont3 etid
- Virginia8 etid
- Washington21 etid
- West Virginia4 etid
- Wisconsin11 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Ap rekriteFaz 1/2
Laj 12 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06303193Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06904066Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Ap rekriteEtid obsèvasyon
1 Day – 99 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT07683104Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06484062Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Ap rekriteFaz 1/2
Laj 4 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT03173937The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07285044A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695CHIP/CCUS Natural History Protocol
Ap rekriteEtid obsèvasyon
Laj 18 a 99 · Tout sèks · Mizajou Sep 28, 2026 · NCT04102423MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06548230Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03661307Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT05320198Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Ap rekriteFaz 2
Laj 4 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT01174108Natural History Study of GATA2 Deficiency and Related Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 22, 2026 · NCT01905826A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07422480Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Ap rekriteFaz 1
Laj 1 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT03630991CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04375631Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187Collection of Tissue Samples for Cancer Research
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03471260Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03683433A Study of BGB-11417 in Participants With Myeloid Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT04771130Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.